Jewish Billionaire Bought Stake In A Malaysian Healthcare Group? Avisena Says No
Avisena Healthcare clarified that KKR & Co, not Henry Kravis personally, is investing in the Malaysian healthcare provider. The undisclosed minority stake is valued between RM300M and RM400M. Avisena's management and operations will remain unchanged. KKR plans to support Avisena's growth, including hospital expansions in the Klang Valley.
How this was made

The 30-second read
Why it matters
The investment expands KKR's healthcare portfolio in APAC and may attract interest in similar deals.
Market read
KKR's deal highlights continued private‑equity activity in Asian healthcare, offering a modest trading catalyst for KKR.
What to watch
Potential regulatory or integration risks in Malaysia that could temper the investment's benefits.
Background
KKR & Co disclosed a definitive agreement to make a minority investment in Avisena Healthcare, a Malaysian provider, rejecting rumors that billionaire Henry Kravis bought the stake personally.
Ticker impact
KKR announced a minority investment in Malaysian healthcare group Avisena Healthcare.
Potential modest upside for KKR shares as investors price in the new Asian healthcare exposure.
KKR's disclosed investment, though size undisclosed, signals continued capital deployment in a growing market.
Market effects
Adds to the trend of private‑equity firms expanding in Asian healthcare, may influence peer PE valuations.
Positive signal for Malaysian healthcare sector and related stocks.
Reinforces KKR's global diversification strategy, modest relevance to broader markets.
Counterpoint
The undisclosed stake size could be small; investors may already price in KKR's Asia exposure, limiting upside.
Key entities
- CompanyKKR & Co
Global investment firm listed on NYSE (ticker KKR).
- CompanyAvisena Healthcare
Malaysian healthcare group receiving the investment.


